drugset
drugset / Trial / NCT03889795

Phase IB Metformin, Digoxin, Simvastatin in Solid Tumors

NCT03889795 ↗

Phase 1 Active not recruiting 15 enrolled Danae Hamouda, MD
NaSequentialOpen-labelTreatment

Summary

This is a single-center trial in subjects with pancreatic cancer and other advanced solid tumors. It is an open-label, single arm dose escalation Phase IB trial with subjects accrued in a 3 subject dose escalation cohort. Subjects with treated advanced solid tumors, and showing disease progression on established standard therapy, will be enrolled in this trial.

Timeline

Start
2019-06-05
Primary completion
2026-12-30
Completion
2027-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.0625 mg Oral
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Digoxin Other / unclassified 0.5 mg Oral
Subject Metformin Small molecule 850 mg Oral
Subject Metformin Small molecule 1700 mg Oral
Subject Simvastatin Small molecule 5 mg Oral
Subject Simvastatin Small molecule 20 mg Oral
Subject Simvastatin Small molecule 40 mg Oral

Indications

malignant pancreatic neoplasm